ASSEMBLY BIOSCIENCES, INC.ASMB決算レポート
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
ASMB Q3 2025 Key Financial Metrics
売上高
$10.8M
粗利益
N/A
営業利益
$-10.9M
純利益
$-9.2M
粗利益率
N/A
営業利益率
-100.9%
純利益率
-85.2%
前年比成長
57.6%
EPS
$-0.72
資金フロー
ASSEMBLY BIOSCIENCES, INC. Q3 2025 財務サマリー
ASSEMBLY BIOSCIENCES, INC. reported revenue of $10.8M (up 57.6% YoY) for Q3 2025, with a net profit of $-9.2M (up 4.3% YoY) (-85.2% margin). Cost of goods sold was N/A.
主要財務指標
| 総売上高 | $10.8M |
|---|---|
| 純利益 | $-9.2M |
| 粗利益率 | N/A |
| 営業利益率 | -100.9% |
| 報告期間 | Q3 2025 |
ASSEMBLY BIOSCIENCES, INC. 年度売上推移
ASSEMBLY BIOSCIENCES, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $28.5M). Click any linked year to see what changed vs the prior 10-K.
ASSEMBLY BIOSCIENCES, INC. 四半期売上・純利益の履歴
ASSEMBLY BIOSCIENCES, INC. quarterly results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q3 2025 | $10.8M | +57.6% | $-9.2M | -85.2% |
| Q2 2025 | $9.6M | +12.8% | $-10.2M | -105.9% |
| Q1 2025 | $9.4M | +62.8% | $-8.8M | -93.6% |
| Q4 2024 | $7.4M | +2.7% | N/A | N/A |
| Q3 2024 | $6.8M | — | $-9.6M | -140.4% |
| Q2 2024 | $8.5M | — | $-11.2M | -130.7% |
| Q1 2024 | $5.8M | — | $-9.1M | -156.9% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| 売上高 | $5.8M | $8.5M | $6.8M | $7.4M | $9.4M | $9.6M | $10.8M |
| 前年比成長 | N/A | N/A | N/A | 2.7% | 62.8% | 12.8% | 57.6% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| 総資産 | $119.9M | $115.3M | $100.3M | $119.2M | $99.0M | $80.8M | $240.0M |
| 総負債 | $87.3M | $80.6M | $74.3M | $85.8M | $71.9M | $62.7M | $57.3M |
| 株主資本 | $32.6M | $34.7M | $26.0M | $33.4M | $27.1M | $18.1M | $182.7M |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| 営業CF | $-18.4M | $-17.1M | $-15.2M | $-51.1M | $-23.4M | $-16.8M | $-15.1M |